Skip to main content
Erschienen in: Drugs 14/2003

01.07.2003 | Therapy in Practice

Acute Exacerbations in Chronic Obstructive Pulmonary Disease

Current Strategies with Pharmacological Therapy

verfasst von: Dr Charles S. Hall, Andreas Kyprianou, Alan M. Fein

Erschienen in: Drugs | Ausgabe 14/2003

Einloggen, um Zugang zu erhalten

Abstract

In acute exacerbation of chronic obstructive pulmonary disease (AECOPD), short-acting inhaled bronchodilators, such as salbutamol (albuterol) and ipratropium bromide, have proven useful. In patients who are refractory to these agents, intravenous aminophylline should be considered. Corticosteroids should also be used, either in the outpatient or inpatient setting. The duration of corticosteroids should probably not exceed 2 weeks and the optimum dosage is yet to be determined. Antibacterials, especially in patients with purulent or increased sputum, should be used, guided by the local antibiogram of the key microbes. Controlled oxygen therapy improves outcome in hypoxaemic patients and arterial blood gases should be performed to ensure hypercarbia is not becoming excessive. Should patients be in distress despite the above measures or if there is acidaemia or hypercarbia, noninvasive positive pressure ventilation could be used to improve outcomes without resorting to invasive mechanical ventilation. Mucous-clearing drugs and chest physiotherapy have no proven beneficial role in AECOPD.
Fußnoten
1
Use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Murray CJ, Lopez AD. Global morality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436–42PubMedCrossRef Murray CJ, Lopez AD. Global morality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436–42PubMedCrossRef
2.
Zurück zum Zitat Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Resp Crit Care Med 2001; 163: 1256–76 Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Resp Crit Care Med 2001; 163: 1256–76
3.
Zurück zum Zitat Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346: 988–94PubMedCrossRef Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346: 988–94PubMedCrossRef
4.
Zurück zum Zitat Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2000; 161: 1608–13PubMed Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2000; 161: 1608–13PubMed
5.
Zurück zum Zitat Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Resp Crit Care Med 2001; 164: 358–64PubMed Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Resp Crit Care Med 2001; 164: 358–64PubMed
6.
Zurück zum Zitat Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204PubMed Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204PubMed
7.
Zurück zum Zitat Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbation of COPD. Chest 1999; 116:40–6PubMedCrossRef Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbation of COPD. Chest 1999; 116:40–6PubMedCrossRef
8.
Zurück zum Zitat McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190–209PubMedCrossRef McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190–209PubMedCrossRef
9.
Zurück zum Zitat Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20PubMed Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20PubMed
10.
Zurück zum Zitat Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134: 595–9PubMed Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134: 595–9PubMed
11.
Zurück zum Zitat COMBIVENT Study Group Investigators. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514–21CrossRef COMBIVENT Study Group Investigators. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514–21CrossRef
12.
Zurück zum Zitat Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolaate and albuterol in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1995; 25: 470–3PubMedCrossRef Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolaate and albuterol in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1995; 25: 470–3PubMedCrossRef
13.
Zurück zum Zitat Shrestha M, O'Brien T, Haddox R, et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy. Ann Emerg Med 1991; 20: 1206–9PubMedCrossRef Shrestha M, O'Brien T, Haddox R, et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy. Ann Emerg Med 1991; 20: 1206–9PubMedCrossRef
14.
Zurück zum Zitat Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50: 834–7PubMedCrossRef Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50: 834–7PubMedCrossRef
15.
Zurück zum Zitat Koutsogiannis Z, Kelly AM. Does high dose ipratropium bromide added to salbutamol improve pulmonary function for patients with chronic obstructive airways disease in the emergency department? Aust N Z J Med 2000; 30: 38–40PubMedCrossRef Koutsogiannis Z, Kelly AM. Does high dose ipratropium bromide added to salbutamol improve pulmonary function for patients with chronic obstructive airways disease in the emergency department? Aust N Z J Med 2000; 30: 38–40PubMedCrossRef
16.
Zurück zum Zitat Maguire GP, Newman T, DeLorenzo LJ, et al. Comparison of a hand-held nebulizer with a metered dose inhaler-spacer combination in acute obstructive pulmonary disease. Chest 1991; 100: 1300–5PubMedCrossRef Maguire GP, Newman T, DeLorenzo LJ, et al. Comparison of a hand-held nebulizer with a metered dose inhaler-spacer combination in acute obstructive pulmonary disease. Chest 1991; 100: 1300–5PubMedCrossRef
17.
Zurück zum Zitat Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction: a meta-analysis. Arch Intern Med 1997; 157: 1736–44PubMedCrossRef Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction: a meta-analysis. Arch Intern Med 1997; 157: 1736–44PubMedCrossRef
18.
Zurück zum Zitat D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119: 1347–56PubMedCrossRef D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119: 1347–56PubMedCrossRef
19.
Zurück zum Zitat Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Resp Crit Care Med 1997; 155: 1283–9PubMed Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Resp Crit Care Med 1997; 155: 1283–9PubMed
20.
Zurück zum Zitat Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117 (2 Suppl.): 63S–6SPubMedCrossRef Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117 (2 Suppl.): 63S–6SPubMedCrossRef
21.
Zurück zum Zitat Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55PubMedCrossRef Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55PubMedCrossRef
22.
Zurück zum Zitat Wrenn K, Slovis C, Murphy F, et al. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann Intern Med 1991; 115: 241–7PubMed Wrenn K, Slovis C, Murphy F, et al. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann Intern Med 1991; 115: 241–7PubMed
23.
Zurück zum Zitat Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease: a controlled trial. Ann Intern Med 1987; 107: 305–9PubMed Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease: a controlled trial. Ann Intern Med 1987; 107: 305–9PubMed
24.
Zurück zum Zitat Cazzola M, Donner CF, Matera MG. Long-acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999; 54(8): 730–6PubMedCrossRef Cazzola M, Donner CF, Matera MG. Long-acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999; 54(8): 730–6PubMedCrossRef
25.
Zurück zum Zitat Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease: Department of Veteran Affairs Cooperative Study. N Engl J Med 1999; 340(25): 1941–7PubMedCrossRef Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease: Department of Veteran Affairs Cooperative Study. N Engl J Med 1999; 340(25): 1941–7PubMedCrossRef
26.
Zurück zum Zitat Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital wit exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456–60PubMedCrossRef Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital wit exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456–60PubMedCrossRef
27.
Zurück zum Zitat Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Resp Crit Care Med 1996; 154: 407–12PubMed Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Resp Crit Care Med 1996; 154: 407–12PubMed
28.
Zurück zum Zitat Sayner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001; 119: 726–30CrossRef Sayner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001; 119: 726–30CrossRef
29.
Zurück zum Zitat Decramer M, Lacquet LM, Fargard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Resp Crit Care Med 1994; 150: 11–6PubMed Decramer M, Lacquet LM, Fargard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Resp Crit Care Med 1994; 150: 11–6PubMed
30.
Zurück zum Zitat Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345–52PubMedCrossRef Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345–52PubMedCrossRef
31.
Zurück zum Zitat Russo RL, D'Aprile M. Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Pharmacother 2001; 35: 576–81PubMedCrossRef Russo RL, D'Aprile M. Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Pharmacother 2001; 35: 576–81PubMedCrossRef
32.
Zurück zum Zitat Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. The Canadian Ciprofloxacin Health Economic Study Group. Chest 1998; 113: 131–41 Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. The Canadian Ciprofloxacin Health Economic Study Group. Chest 1998; 113: 131–41
33.
Zurück zum Zitat Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22PubMedCrossRef Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22PubMedCrossRef
34.
Zurück zum Zitat Plant PK, Owen JL, Elliot MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicenter randomized controlled trial. Lancet 2000; 355: 1931–5PubMedCrossRef Plant PK, Owen JL, Elliot MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicenter randomized controlled trial. Lancet 2000; 355: 1931–5PubMedCrossRef
35.
Zurück zum Zitat Plant PK, Owen JL, Elliot MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax 2001; 56: 708–12PubMedCrossRef Plant PK, Owen JL, Elliot MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax 2001; 56: 708–12PubMedCrossRef
36.
Zurück zum Zitat Keenan SP, Gregor J, Sibbald WJ, et al. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med 2000; 28: 2094–102PubMedCrossRef Keenan SP, Gregor J, Sibbald WJ, et al. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med 2000; 28: 2094–102PubMedCrossRef
37.
Zurück zum Zitat Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8(8): 1398–420 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8(8): 1398–420
38.
Zurück zum Zitat Wollmer P, Ursing K, Midgren B, et al. Inefficiency of chest percussion in the physical therapy or chronic bronchitis. Eur J Respir Dis 1985; 66: 233–9PubMed Wollmer P, Ursing K, Midgren B, et al. Inefficiency of chest percussion in the physical therapy or chronic bronchitis. Eur J Respir Dis 1985; 66: 233–9PubMed
Metadaten
Titel
Acute Exacerbations in Chronic Obstructive Pulmonary Disease
Current Strategies with Pharmacological Therapy
verfasst von
Dr Charles S. Hall
Andreas Kyprianou
Alan M. Fein
Publikationsdatum
01.07.2003
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 14/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363140-00004

Weitere Artikel der Ausgabe 14/2003

Drugs 14/2003 Zur Ausgabe